Oncology Small Molecule Drugs Market size is done based on a triangulation methodology that is primarily based on experimental modelling approaches such as patient-level data or disease epidemiology for any key indications , number of procedures and install base analysis for any equipment to obtain precise market estimations for the base year as well as in historic data analysis. Bottom-up approach is always used to obtain Oncology Small Molecule Drugs insightful data for the specific country/regions.
The country specific data is again analyzed to derive data at a global level. Specific factors/parameters are considered related to the individual Oncology Small Molecule Drugs market and quantified with insightful rationale.
For More Insights Into The Market, Request a Sample of this Report –https://www.factmr.com/connectus/sample?flag=S&rep_id=3747
Key Takeaways from the Market Study:
- The global oncology small molecule drugs market is anticipated to add 1.8x value by 2031
- Oral oncology small molecule drugs generated over US$ 56 Bn in revenue as of 2019
- By drug class, targeted therapy drugs to reign supreme, capturing nearly 50% revenue
- Immunomodulating drugs to hold noteworthy share, surpassing US$ 13 Bn by 2031
- Non small-cell lung cancer (NSCLC) remains core indication area through 2031
- U.S to account for 50% of global demand, surpassing US$ 30 Bn in 2019
- China to contribute 55% of overall market revenue across the forecast period
Key Segments Covered
- Route of Administration
- Oral Oncology Small Molecule Drugs
- Injectable Oncology Small Molecule Drugs
- Drug Class
- Small Molecule Chemotherapy Drugs
- Alkylating Drugs
- Antimetabolites
- Other Drugs
- Small Molecule Immunomodulating Drugs
- Small Molecule Targeted Therapy Drugs
- Proteasome Inhibitors
- Tyrosine Kinase Inhibitors
- mTOR Inhibitors
- Hormonal Therapy
- Small Molecule Chemotherapy Drugs
- Distribution Channel
- Oncology Small Molecule Drugs Distribution via Hospital Pharmacies
- Oncology Small Molecule Drugs Distribution via Retail Pharmacies
- Oncology Small Molecule Drugs Distribution via Specialty clinics
- Oncology Small Molecule Drugs Distribution via Online Pharmacies
- Indication
- Oncology Small Molecule Drugs for Non-small Cell Lung Cancer
- Oncology Small Molecule Drugs for Renal Cell Carcinoma
- Oncology Small Molecule Drugs for Breast Cancer
- Oncology Small Molecule Drugs for Prostate Cancer
- Oncology Small Molecule Drugs for Multiple Myeloma
- Oncology Small Molecule Drugs for Melanoma
- Oncology Small Molecule Drugs for Lymphoma
- Oncology Small Molecule Drugs for Leukaemia
- Oncology Small Molecule Drugs for Other Indications
Key Companies Profiled
- Novartis AG
- Pfizer Inc.
- Amgen Plc.
- F. Hoffmann-La Roche Ltd.
- Eli Lilly and Company
- Sanofi SA
- Bristol-Myers Squibb Company
- AbbVie Inc.
- Bayer AG
- Incyte Corporation
- Celgene Corporation
- AstraZeneca Plc.
- Exelixis Inc.
- Millennium Pharmaceuticals Inc. (Takeda)